Effect of Oral JTT-751 (Ferric Citrate) on Hyperphosphatemia in Hemodialysis Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Prevention and Control of Phosphate Retention/Hyperphosphatemia in CKD-MBD: What Is Normal, When to Start, and How to Treat?

(2011) K. J. Martin et al.   Clinical Journal of the American Society of Nephrology

Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia

(2011) T. Shigematsu et al.   CLINICAL NEPHROLOGY

PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease

(2011) P. Geisser et al.   CLINICAL NEPHROLOGY

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride

(2011) JIN-BOR CHEN et al.   NEPHROLOGY

Efficacy and safety of SBR759, a new iron-based phosphate binder

(2010) Geoffrey A. Block et al.   KIDNEY INTERNATIONAL

International trends in erythropoietin use and hemoglobin levels in hemodialysis patients

(2010) Philip A. McFarlane et al.   KIDNEY INTERNATIONAL

Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin

(2010) Takeshi Hasegawa et al.   KIDNEY INTERNATIONAL

Hyperphosphatemia of chronic kidney disease

(2008) Keith A. Hruska et al.   KIDNEY INTERNATIONAL

Lanthanum Carbonate Effectively Controls Serum Phosphate Without Affecting Serum Calcium Levels in Patients Undergoing Hemodialysis

(2008) Takashi Shigematsu et al.   THERAPEUTIC APHERESIS AND DIALYSIS